ElevateBio Reports Sixth Consecutive Year of Revenue Growth with 98% Manufacturing Success Rate
Key Insights
ElevateBio (search) achieved its sixth consecutive year of revenue growth while maintaining a 98% manufacturing batch success rate across cell therapy, viral vector, and mRNA production at its BaseCamp (search) facility.
The company appointed Christopher Murphy (search) as CEO to lead expansion efforts, leveraging his 35+ years of experience in biopharmaceutical development and manufacturing operations.
ElevateBio (search) expanded its gene editing capabilities by adding targeted insertion and epigenetic editing modalities to Life Edit (search)'s platform, while supporting 18 preclinical and clinical-stage programs.
ElevateBio (search) has reported its sixth consecutive year of revenue growth, driven by significant expansion of its integrated cell and gene therapy development and manufacturing capabilities. The technology-driven genetic medicine company achieved a remarkable 98% manufacturing batch success rate across cell therapy, viral vector, and mRNA production at its BaseCamp (search) facility.
Leadership Transition and Strategic Growth
The company appointed Christopher Murphy (search) as Chief Executive Officer and Board member, succeeding Ger Brophy (search), who served as interim CEO since May 2025. Murphy brings over 35 years of leadership experience across biopharmaceutical and manufacturing sectors, including previous roles as CEO of Akron Bio (search) and Chief Operating Officer of Brammer Bio (search).
"Chris is an exceptional fit to lead the ElevateBio (search) team to capture the momentum of the genetic medicine industry's next wave of expansion," said David Hallal (search), Executive Chairman of ElevateBio. "His proven success and deep expertise in development and large-scale manufacturing are essential as more partners entrust us with their programs as they mature in development and require consistent, high-quality product for commercialization."
Murphy emphasized the company's unique position in the market: "As the only company spanning genetic medicine design, development, and manufacturing, ElevateBio (search) is uniquely positioned to move the cell and gene therapy field from scientific novelty to maturity."
Manufacturing Excellence and Global Expansion
ElevateBio (search)'s BaseCamp (search) facility demonstrated exceptional operational performance in 2025, achieving a 98% manufacturing batch success rate across multiple therapeutic modalities. The company received Initiative for Certification of Manufacturing Capabilities (ICMC) certification from Dark Horse Consulting (search), validating its compliant, scalable, and commercial manufacturing capabilities using U.S. and E.U. commercial-level evaluation standards.
The company expanded its manufacturing footprint significantly, increasing capacity at its flagship Waltham, Massachusetts facility by 30% through the addition of multiple large, Grade B advanced therapy manufacturing suites. Construction of a new BaseCamp (search) facility in Pittsburgh, Pennsylvania reached shell completion, with full construction anticipated by Q4 2026 and operational status expected in 2027.
ElevateBio (search) now supports genetic medicine supply capabilities across North America, South America, Europe, Asia, and Australia, positioning itself as a global manufacturing hub for advanced therapies.
Technology Platform Advancement
The company's Life Edit (search) gene editing platform expanded its capabilities by adding targeted insertion and epigenetic editing modalities to its existing nuclease editing, base editing, and reverse transcriptase editing technologies. This expansion broadens the range of diseases addressable through partnerships.
Life Edit (search) achieved significant technological milestones, including high potency base editing in the liver delivered via proprietary lipid nanoparticles in non-human primates, resulting in greater than 70% reduction of target protein expression. The platform also demonstrated RT editing gene correction of approximately 30% in murine liver models.
AI-Powered Discovery Acceleration
ElevateBio (search) implemented generative artificial intelligence powered by protein language models trained on experimental data from Life Edit (search)'s collection of natural and synthetic CRISPR (search) enzymes. This AI integration accelerated target selection to proof-of-concept for target editing from nine months to three months and successfully generated two million unique deaminase sequences for novel base editor discovery.
Portfolio Growth and Manufacturing Expansion
The company supported 18 preclinical and clinical-stage programs across its contract manufacturing portfolio and partnered therapeutic pipeline. ElevateBio (search) completed or initiated nearly 10 technology transfers spanning autoimmune disease (search), oncology (search), rare diseases (search), and vaccines.
The addition of mRNA to its GMP-grade manufacturing capabilities expanded BaseCamp (search)'s modality support across diverse therapeutic approaches. The company also evaluated more than 10 emerging technologies through its Emerging Technology Lab, including automated cell processing platforms, microfluidics-based systems, and novel delivery methods.
Financial Position and Market Outlook
ElevateBio (search) maintained a strong cash position with multiple years of operating runway despite challenging market conditions. The company supported a growing number of programs in late-stage development nearing commercialization, including CMC regulatory strategy and submission writing for biologics license applications.
"ElevateBio (search) has built a remarkably resilient business advancing the genetic medicine space, which is increasingly demonstrating its ability to transform the field of medicine by addressing previously untreatable conditions," said Chris Murphy. "Our integrated model across discovery, development, and manufacturing continues to resonate with partners seeking a reliable, technology-driven path forward for their therapeutic programs."